<DOC>
	<DOCNO>NCT01930708</DOCNO>
	<brief_summary>The primary objective study estimate annualized relapse rate ( ARR ) participant Relapsing Remitting Multiple Sclerosis ( RRMS ) treat dimethyl fumarate ( DMF ) 12-month period . The secondary objective study population assess impact DMF 12-month period participant -reported health-related quality life ( HRQoL ) outcomes , additional clinical effectiveness outcome , health economics-related outcome , characterize participants-reported adherence DMF .</brief_summary>
	<brief_title>A Study Evaluating Effectiveness Tecfidera ( Dimethyl Fumarate ) Multiple Sclerosis ( MS ) Disease Activity Patient-Reported Outcomes</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Have diagnosis RelapsingRemitting Multiple Sclerosis ( RRMS ) satisfy approve therapeutic indication DMF ( per local DMF product information ) . Must naïve DMF , Fumaderm® , compound fumarates , MS therapies primarily prescribe secondline ( e.g. , natalizumab , fingolimod ) alemtuzumab . Have recent complete blood count ( CBC ) preclude subject 's participation study , judgment Investigator . Key Are unwilling unable comply study requirement , deem unsuitable study participation determine Investigator . Have major comorbid condition preclude participation study , determine Investigator . Are pregnant , unless DMF clearly need potential benefit DMF subject justify potential risk fetus , judgment Investigator ( country except Austria ) . In Austria , pregnant subject exclude participation study . Are woman childbearing potential use appropriate contraception ( per local DMF product information ) determine Investigator . Women breastfeed may exclude ( per local DMF product information ) discretion Investigator . Have previously receive receive treatment MS therapy primarily use secondline ( e.g. , natalizumab , fingolimod ) alemtuzumab , currently receive plan continue diseasemodifying therapy RRMS . Are hypersensitive active ingredient DMF drug product ( i.e. , DMF ) excipients list local DMF product information . Current enrollment clinical trial except Biogen Idec DMF Pregnancy Exposure Registry study , accord study Medical Director , conflict study ( e.g. , health economics study local registry ) . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>BG-12</keyword>
</DOC>